反射性ミオクローヌスを認めたBickerstaff脳幹脳炎の1例

Takaki, Ryusuke; Nagasaka, Takamura; Suwa, Yumi; Tsuchiya, Mai; Kho, Kishin; Takiyama, Yoshihisa

doi:10.5692/clinicalneurol.cn-001026

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The three other patients presented with AIDP and had negative anti-ganglioside screening. While our patient presented myoclonus limited to the palatal region, myoclonus has already been described in BBE [7]. Anti-GD1b have been described in the clinical spectrum of GBS-classically in acute sensory ataxic neuropathy (ASAN), but also in AMSAN-, MFS and BBE, and are associated with more severe disease and slower recovery [5,8,9].…”

Section: Discussionsupporting

confidence: 50%

SARS-CoV-2-associated Guillain–Barré syndrome in four patients: what do we know about pathophysiology?

et al. 2021

View full text Add to dashboard Cite

Background A growing number of Guillain-Barré syndrome (GBS) and Miller Fisher Syndrome (MFS) cases following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are reported. Nevertheless, this association is still debated, and pathophysiology remains unclear. Methods Between April and December 2020, in three hospitals located in Brussels, Belgium, we examined four patients with GBS following SARS-CoV-2 infection. Results Neurological onset occurred 3 weeks after SARS-CoV-2 symptoms in all patients. Three patients presented with acute inflammatory demyelinating polyneuropathy (AIDP) and had negative anti-ganglioside testing: two suffered from a severe SARS-CoV-2 infection and had good clinical outcome after intravenous immunoglobulin (IVIG) treatment; one with mild SARS-CoV-2 infection had spontaneously favorable evolution without treatment. The fourth patient had critical SARS-CoV-2 infection and presented acute motor and sensory axonal neuropathy (AMSAN) with clinical features highly suggestive of brainstem involvement, as well as positive anti-ganglioside antibodies (anti-GD1b IgG) and had partial improvement after IVIG. Conclusions We report four cases of SARS-CoV-2-associated GBS. The interval of 3 weeks between SARS-CoV-2 symptoms and neurological onset, the clinical improvement after IVIG administration, and the presence of positive anti-ganglioside antibodies in one patient further support the hypothesis of an immune-mediated post-infectious process. Systematic extensive antibody testing might help for a better understanding of physiopathology.

show abstract